➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Dow
Moodys
Boehringer Ingelheim
McKesson

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZONEGRAN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Zonegran

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00056576 ↗ Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy Completed Eisai Inc. Phase 3 2002-02-01 The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.
NCT00203450 ↗ Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial Completed Eisai Inc. Phase 4 2003-05-01 The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.
NCT00203450 ↗ Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial Completed Tuscaloosa Research & Education Advancement Corporation Phase 4 2003-05-01 The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.
NCT00215592 ↗ Open Label, Zonegran (Zonisamide) In Partial Onset Seizures Completed Eisai Limited Phase 4 2005-10-01 To determine the efficacy and safety of adjunctive open label Zonegran treatment in patients with refractory partial seizures.
NCT00221442 ↗ Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed Eisai Inc. Phase 3 2005-08-01 The specific aim of this study is to examine the efficacy and safety of zonisamide compared with placebo in outpatients with binge eating disorder associated with obesity.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zonegran

Condition Name

Condition Name for Zonegran
Intervention Trials
Healthy 6
Epilepsy 2
Obesity 2
Hearing Loss, Noise-Induced 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zonegran
Intervention Trials
Hearing Loss, Noise-Induced 2
Obesity 2
Hearing Loss 2
Deafness 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zonegran

Trials by Country

Trials by Country for Zonegran
Location Trials
United States 27
Austria 2
Denmark 1
Italy 1
Finland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zonegran
Location Trials
Ohio 3
Florida 3
West Virginia 2
North Carolina 2
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zonegran

Clinical Trial Phase

Clinical Trial Phase for Zonegran
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zonegran
Clinical Trial Phase Trials
Completed 12
Not yet recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zonegran

Sponsor Name

Sponsor Name for Zonegran
Sponsor Trials
Eisai Inc. 4
Mylan Pharmaceuticals 2
Gateway Biotechnology, Inc. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zonegran
Sponsor Trials
Industry 15
Other 10
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Johnson and Johnson
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.